Measuring Treatment Tolerability in Oncology: Expert Panel Discussion

Traditional adverse event reporting often fails to capture the complete patient experience of treatment burden in oncology trials—research shows clinicians can miss up to 50% of patient-reported symptoms.

Pharmaceutical sponsors need comprehensive strategies to measure and interpret patient-reported tolerability data that satisfy regulatory expectations while informing critical development decisions.

This on-demand webinar brings together oncology development leaders from across industry and academia to share actionable approaches for assessing overall side effect burden, implementing phase-appropriate tolerability measures, and translating PRO data into meaningful insights for submissions and labeling.

Featured Speakers:

• Bill Byrom, PhD – Vice President, eCOA Science, Signant Health
• Todd Everhart, MD – Clinical Vice President, Signant Health
• Professor Devin Peipert, PhD – University of Birmingham
• Josh Biber, PhD, MBA, MS – Takeda

Discover how to bridge the gap between individual adverse events and holistic tolerability interpretations that strengthen your oncology development program.